Sartorius Stedim Biotech SA
LSE:0RG8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sartorius Stedim Biotech SA
LSE:0RG8
|
FR |
|
S
|
Saf-Holland Se
F:SFQ
|
DE |
|
P
|
Perk Labs Inc
CNSX:PERK
|
CA |
|
P
|
Petroleo Brasileiro SA Petrobras
XBER:PJX
|
BR |
|
Schweizer Electronic AG
LSE:0MOE
|
DE |
|
S
|
SGL Carbon SE
OTC:SGLFF
|
DE |
|
I
|
Innovative Industrial Properties Inc
LSE:0JBD
|
US |
|
Gunnison Copper Corp
F:3XS0
|
US |
|
M
|
Manyo Factory Co Ltd
KOSDAQ:439090
|
KR |
|
Anheuser-Busch Inbev SA
MIL:ABI
|
BE |
|
Derichebourg SA
PAR:DBG
|
FR |
|
I
|
Illinois Tool Works Inc
F:ILT
|
US |
Wall St Price Targets
0RG8 Price Targets Summary
Sartorius Stedim Biotech SA
According to Wall Street analysts, the average 1-year price target for 0RG8 is 236.46 EUR with a low forecast of 212.36 EUR and a high forecast of 275.44 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0RG8's stock price target?
Price Target
236.46
EUR
According to Wall Street analysts, the average 1-year price target for 0RG8 is 236.46 EUR with a low forecast of 212.36 EUR and a high forecast of 275.44 EUR.
What is the Revenue forecast for Sartorius Stedim Biotech SA?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 8 years is 12%.
What is the Operating Income forecast for Sartorius Stedim Biotech SA?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 8 years is 17%.
What is the Net Income forecast for Sartorius Stedim Biotech SA?
Projected CAGR
23%
Over the last 13 years, the compound annual growth rate for Net Income has been 13%. The projected CAGR for the next 8 years is 23%.
